Rp-8-Bromo-β-phenyl-1,N2-ethenoguanosine 3′,5′-cyclic monophosphorothioate sodium salt
SIGMA/B6684 - ≥98% (HPLC), powder
Synonym: Rp-β-Phenyl-1,N2-etheno-8-bromoguanosine 3′,5′-cyclic monophosphorothioate sodium salt; Rp-8-Br-PET-cGMPS
CAS Number: 185246-32-6
Empirical Formula (Hill Notation): C18H14BrN5NaO6PS
Molecular Weight: 562.27
Linear Formula: C18H14BrN5NaO6PS
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C18H15BrN5O6PS.Na/c19- |
| InChI key | SVMPQLHYWRTQCX-DBHVCDLJSA |
| mp | 240-300 °C (lit.) |
| potency | 30 nM Ki |
| Quality Level | 100 ![]() |
| SMILES string | O.[Na+].O[C@@H]1[C@@H]2O[ |
| solubility | H2O: 15 mg/mL at ≤60 °C |
| storage temp. | −20°C |
| Biochem/physiol Actions: | Rp-8-Br-PET-cGMPS is a metabolically stable, competitive inhibitor of both PKG I (Ki = 30 nM) and PKG II. Blocks cGMP-gated retinal type ion channels (IC50 = 25 micromoles). |
| Biochem/physiol Actions: | Rp-8-Br-PET-cGMPS is metabolically stable, competitive inhibitor of cGMP-dependent protein kinase G. Inhibits both PKG I (Ki = 30 nM) and PKG II and blocks cGMP-gated retinal type ion channels (IC50 = 25 micromoles). |
| Features and Benefits: | This compound is featured on the PKA & PKG page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Legal Information: | U.S. Patent 5,625,056, DE Patent 4,217,679. |
| Packaging: | 1, 5 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| mp | 240-300 °C (lit.) |
| Storage Temp. | −20°C |
| UNSPSC | 41106305 |

